[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020013100A - Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. - Google Patents

Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.

Info

Publication number
MX2020013100A
MX2020013100A MX2020013100A MX2020013100A MX2020013100A MX 2020013100 A MX2020013100 A MX 2020013100A MX 2020013100 A MX2020013100 A MX 2020013100A MX 2020013100 A MX2020013100 A MX 2020013100A MX 2020013100 A MX2020013100 A MX 2020013100A
Authority
MX
Mexico
Prior art keywords
mucositis
host disease
prevention
treatment
versus host
Prior art date
Application number
MX2020013100A
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of MX2020013100A publication Critical patent/MX2020013100A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de una proteína CD24 para prevenir o tratar enfermedad de injerto contra hospedero y mucositis.
MX2020013100A 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. MX2020013100A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862680218P 2018-06-04 2018-06-04
US201862739719P 2018-10-01 2018-10-01
US201862739742P 2018-10-01 2018-10-01
PCT/US2019/035200 WO2019236472A1 (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis

Publications (1)

Publication Number Publication Date
MX2020013100A true MX2020013100A (es) 2021-02-17

Family

ID=68770596

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013103A MX2020013103A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
MX2020013100A MX2020013100A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020013103A MX2020013103A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.

Country Status (15)

Country Link
US (2) US20210228680A1 (es)
EP (2) EP3802583A4 (es)
JP (2) JP2021527056A (es)
KR (2) KR20210021317A (es)
CN (2) CN112752766A (es)
AU (2) AU2019282044A1 (es)
BR (2) BR112020024659A2 (es)
CA (2) CA3102374A1 (es)
CL (2) CL2020003169A1 (es)
IL (2) IL279204A (es)
MA (2) MA52810A (es)
MX (2) MX2020013103A (es)
SG (2) SG11202011963UA (es)
TW (2) TW202012015A (es)
WO (2) WO2019236472A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202012015A (zh) * 2018-06-04 2020-04-01 美商昂科免疫公司 以cd24預防及治療白血病復發之方法
WO2021160173A1 (en) * 2020-02-10 2021-08-19 Oncoimmune, Inc. Methods of use of soluble cd24 for treating viral pneumonia
WO2023205742A1 (en) * 2022-04-20 2023-10-26 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US8614301B2 (en) * 2007-11-14 2013-12-24 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of treating cancer using anti CD24 antibodies
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
NO2563385T3 (es) * 2010-04-28 2017-12-30
CN102250828B (zh) * 2010-11-10 2014-11-05 北京大学 Cd24及cd24抗体的新用途
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
CN107207597A (zh) * 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
MX2017014095A (es) * 2015-05-07 2018-03-16 Oncoimmune Inc Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad.
WO2017136492A1 (en) 2016-02-02 2017-08-10 Oncoimmune, Inc. Use of cd24 proteins for treating leptin-deficient conditions
TW202012015A (zh) * 2018-06-04 2020-04-01 美商昂科免疫公司 以cd24預防及治療白血病復發之方法
WO2021142336A1 (en) * 2020-01-08 2021-07-15 Puretech Lyt, Inc. Vesicle compositions for oral delivery

Also Published As

Publication number Publication date
JP2021527066A (ja) 2021-10-11
CA3102372A1 (en) 2019-12-12
EP3802583A1 (en) 2021-04-14
IL279205A (en) 2021-01-31
MX2020013103A (es) 2021-05-12
SG11202011964SA (en) 2020-12-30
EP3801773A1 (en) 2021-04-14
US20210268061A1 (en) 2021-09-02
SG11202011963UA (en) 2020-12-30
TW202015753A (zh) 2020-05-01
BR112020024659A2 (pt) 2021-03-09
CA3102374A1 (en) 2019-12-12
JP2021527056A (ja) 2021-10-11
CL2020003168A1 (es) 2021-06-11
WO2019236474A1 (en) 2019-12-12
WO2019236472A1 (en) 2019-12-12
TW202012015A (zh) 2020-04-01
AU2019282530A1 (en) 2021-01-07
EP3801773A4 (en) 2022-03-16
CN112752766A (zh) 2021-05-04
US20210228680A1 (en) 2021-07-29
KR20210021317A (ko) 2021-02-25
MA52811A (fr) 2022-03-16
IL279204A (en) 2021-01-31
BR112020024683A2 (pt) 2021-03-09
AU2019282044A1 (en) 2021-01-07
US11911441B2 (en) 2024-02-27
MA52810A (fr) 2021-04-14
KR20210018294A (ko) 2021-02-17
CN112512640A (zh) 2021-03-16
EP3802583A4 (en) 2022-03-16
CL2020003169A1 (es) 2021-06-11

Similar Documents

Publication Publication Date Title
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
SG11202012070YA (en) Methods and compositions for preventing or treating tissue calcification
EP3968916A4 (en) GLAND TREATMENT DEVICES AND METHODS OF TREATING DRY EYE DISEASE
EA202191358A1 (ru) Новые соединения и их применение в лечении
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MX2022001626A (es) Composiciones biofarmaceuticas y procedimientos conexos.
MX2021003262A (es) Metodos de tratamiento.
BR112022003935A2 (pt) Rebamipida para uso em profilaxia e tratamento de doença celíaca
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2021003265A (es) Metodos de tratamiento.
MX2021001393A (es) Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.